{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:14:03Z","timestamp":1771409643955,"version":"3.50.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":401,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K12895"],"award-info":[{"award-number":["22K12895"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K12895"],"award-info":[{"award-number":["22K12895"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio-oncology has received increasing attention owing to the cardiotoxic effects of anti-cancer therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to evaluate the clinical characteristics and outcomes of patients with heart failure (HF) who received chemotherapy compared with those of a matched cohort with HF who did not receive chemotherapy, using real-world HF data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was based on the Diagnosis Procedure Combination (DPC) database of the Japanese Registry of All Cardiac and Vascular Diseases (JROAD). We identified 1 328 113 patients who were hospitalized for HF between April 2012 and March 2021. The propensity score (PS) was estimated using a logistic regression model, with chemotherapy as the dependent variable, and a clinically score-matched analysis of 11 532 patients with HF with or without chemotherapy. The primary endpoint was readmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Colon, lung, breast and prostate cancers accounted for &amp;gt;60% of all cancer types. After PS matching, readmission was significantly more frequently observed in patients with chemotherapy than those without [odds ratio (OR), 1.26; 95% confidence interval (CI) 1.17\u20131.36, P &amp;lt; 0.01]. In particular, treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (OR, 1.69; 95% CI 1.39\u20132.07), taxane (OR, 2.95; 95% CI 2.11\u20134.12), anthracyclines (OR, 1.86; 95% CI 1.19\u20132.90) and fluorouracil agents (OR, 1.65; 95% CI 1.18\u20132.30) caused a higher risk of readmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Medical providers need to monitor and follow-up patients with HF, depending on the characteristics of the anti-cancer agents and types of cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15204","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T03:39:32Z","timestamp":1736739572000},"page":"1965-1976","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Evaluation and Outcome in Heart Failure Patients Receiving Chemotherapy with Different Anti-Cancer Agents"],"prefix":"10.1093","volume":"12","author":[{"given":"Tomiko","family":"Sunaga","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmaceutics, School of Pharmacy, Showa University , Tokyo ,","place":["Japan"]},{"name":"Division of Applied Pharmaceutical Education and Research, Hoshi University , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, School of Pharmacy, Showa University , Tokyo ,","place":["Japan"]},{"name":"Department of Pharmacy, Showa University Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Iso","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Ebato","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Toshida","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Nawata","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, School of Pharmacy, Showa University , Tokyo ,","place":["Japan"]},{"name":"Department of Pharmacy, Showa University Northern Yokohama Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Kogo","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"2026021804260183600_ehf215204-bib-0001","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026021804260183600_ehf215204-bib-0002","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ejhf.1594","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis","volume":"21","author":"Jones","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021804260183600_ehf215204-bib-0003","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026021804260183600_ehf215204-bib-0004","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2026021804260183600_ehf215204-bib-0005","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804260183600_ehf215204-bib-0006","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/ejhf.1569","article-title":"Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise","volume":"21","author":"Moliner","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021804260183600_ehf215204-bib-0007","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.hfc.2022.01.001","article-title":"Spectrum of National Institutes of Health-funded research in cardio-oncology: a basic, clinical, and observational science perspective","volume":"18","author":"Adhikari","year":"2022","journal-title":"Heart Fail Clin"},{"key":"2026021804260183600_ehf215204-bib-0008","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.hfc.2022.02.002","article-title":"Clinical practice guidelines in cardio-oncology","volume":"18","author":"Leong","year":"2022","journal-title":"Heart Fail Clin"},{"key":"2026021804260183600_ehf215204-bib-0009","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10549-022-06753-7","article-title":"The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis","volume":"198","author":"Wu","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"2026021804260183600_ehf215204-bib-0010","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-002053","article-title":"Cardiotoxicity of adjuvant chemotherapy with trastuzumab: a Japanese claim-based data analysis","volume":"9","author":"Ohtsu","year":"2022","journal-title":"Open Heart"},{"key":"2026021804260183600_ehf215204-bib-0011","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaoncol.2016.1269","article-title":"Trastuzumab-related cardiotoxic effects in Taiwanese women: a nationwide cohort study","volume":"2","author":"Chien","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026021804260183600_ehf215204-bib-0012","volume-title":"Cancer statistics in Japan\u20142021","year":"2021"},{"key":"2026021804260183600_ehf215204-bib-0013","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/ejhf.319","article-title":"Heart failure as a general pandemic in Asia","volume":"17","author":"Shimokawa","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026021804260183600_ehf215204-bib-0014","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3322\/caac.21727","article-title":"Oncologic emergencies and urgencies: a comprehensive review","volume":"72","author":"Gould Rothberg","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2026021804260183600_ehf215204-bib-0015","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2012.42.8375","article-title":"American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology","volume":"30","author":"Schnipper","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026021804260183600_ehf215204-bib-0016","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-230499","article-title":"Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug","volume":"12","author":"Mishra","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2026021804260183600_ehf215204-bib-0017","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"2026021804260183600_ehf215204-bib-0018","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"2026021804260183600_ehf215204-bib-0019","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008011.pub3","article-title":"Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer","volume":"2016","author":"Cheuk","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021804260183600_ehf215204-bib-0020","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2026021804260183600_ehf215204-bib-0021","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"2026021804260183600_ehf215204-bib-0022","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/annonc\/mdf132","article-title":"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients","volume":"13","author":"Jensen","year":"2002","journal-title":"Ann Oncol"},{"key":"2026021804260183600_ehf215204-bib-0023","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl Med"},{"key":"2026021804260183600_ehf215204-bib-0024","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026021804260183600_ehf215204-bib-0025","doi-asserted-by":"publisher","first-page":"6677","DOI":"10.3390\/molecules26216677","article-title":"Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism","volume":"26","author":"Abourehab","year":"2021","journal-title":"Molecules"},{"key":"2026021804260183600_ehf215204-bib-0026","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026021804260183600_ehf215204-bib-0027","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"Totzeck","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2026021804260183600_ehf215204-bib-0028","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.4103\/jcecho.jcecho_4_19","article-title":"Peripheral artery disease and stroke","volume":"30","author":"Zito","year":"2020","journal-title":"J Cardiovasc Echogr"},{"key":"2026021804260183600_ehf215204-bib-0029","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"38","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021804260183600_ehf215204-bib-0030","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","article-title":"Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety","volume":"16","author":"Verstovsek","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026021804260183600_ehf215204-bib-0031","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies","volume":"13","author":"Cheikh","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026021804260183600_ehf215204-bib-0032","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.739044","article-title":"Anti-cancer drugs associated atrial fibrillation\u2014an analysis of real-world pharmacovigilance data","volume":"9","author":"Ahmad","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026021804260183600_ehf215204-bib-0033","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021804260183600_ehf215204-bib-0034","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3390\/jcm9103346","article-title":"Hypertensive cardiotoxicity in cancer treatment\u2014systematic analysis of adjunct, conventional chemotherapy, and novel therapies\u2014epidemiology, incidence, and pathophysiology","volume":"9","author":"Chung","year":"2020","journal-title":"J Clin Med"},{"key":"2026021804260183600_ehf215204-bib-0035","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ijc.34024","article-title":"The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction","volume":"151","author":"Bouwer","year":"2022","journal-title":"Int J Cancer"},{"key":"2026021804260183600_ehf215204-bib-0036","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026021804260183600_ehf215204-bib-0037","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer therapy-related hypertension: a scientific statement from the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"2026021804260183600_ehf215204-bib-0038","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.3390\/jcm11113133","article-title":"Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients\u2014a systematic review and meta-analysis","volume":"11","author":"Boszkiewicz","year":"2022","journal-title":"J Clin Med"},{"key":"2026021804260183600_ehf215204-bib-0039","volume-title":"About policy","author":"Ministry of Health, Labour and Welfare of Japan"},{"key":"2026021804260183600_ehf215204-bib-0040","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1177\/1078155218798138","article-title":"Impact of pharmacy collaborating services in an outpatient clinic on improving adverse drug reactions in outpatient cancer chemotherapy","volume":"25","author":"Suzuki","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2026021804260183600_ehf215204-bib-0041","doi-asserted-by":"publisher","first-page":"681","DOI":"10.5649\/jjphcs.46.681","article-title":"Evaluation of the collaboration system between community pharmacies and hospital for the management of oral anti-cancer therapy using information sharing tools and team-based learning","volume":"46","author":"Ueda","year":"2020","journal-title":"Iryoyakugaku"},{"key":"2026021804260183600_ehf215204-bib-0042","volume-title":"Diagnosis and treatment performance, research performance, and clinical indicators. Medical safety indicators"},{"key":"2026021804260183600_ehf215204-bib-0043","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jemermed.2019.09.032","article-title":"Emergency ambulatory management of low-risk febrile neutropenia: Multinational Association for Supportive Care in Cancer fits\u2014real-world experience from a UK cancer center","volume":"58","author":"Marshall","year":"2020","journal-title":"J Emerg Med"},{"key":"2026021804260183600_ehf215204-bib-0044","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajem.2023.02.012","article-title":"Clinical factors predicting return emergency department visits in chemotherapy-induced febrile neutropenia patients","volume":"67","author":"Heo","year":"2023","journal-title":"Am J Emerg Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1965\/66956137\/eschf_12_3_1965.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1965\/66956137\/eschf_12_3_1965.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:26:07Z","timestamp":1771406767000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/3\/1965\/8488344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,13]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15204","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"2024-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}